Nabriva Therapeutics PLC

NASDAQ:NBRVUnited States

Nabriva Therapeutics plc is a biopharmaceutical company. The Company is engaged in the commercialization and research and development of anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.

Contact Information

Headquarters

Alexandra House Office 225/227 , The Sweepstakes,, BallsbridgeDUBLIN, Ireland D01 H104

Phone

610-816-6640

Fax

---

Executives

Independent Chairman of the Board

Daniel Burgess

Interim Chief Executive Officer, General Counsel, Secretary

J. Christopher Naftzger

Chief Financial Officer

Daniel Dolan

Chief Medical Officer

Christine Guico-Pabia

Director

Colin Broom